Table 1.
Baseline characteristics of the sample
| Total samplea (n = 169) | Early-phase (n = 108) | Later-phase (n = 59) | |
|---|---|---|---|
| Male gender, n (%) | 114 (67.5%) | 75 (69.4%) | 38 (64.4%) |
| Age at consent (years), mean (SD) | 32.9 (12.2) | 28.0 (9.4) | 41.6 (11.9) |
| AOM mean dose (mg), mean (SD) | 371.6 (50.2) | 371.3 (53.0) | 371.2 (45.7) |
| GAF score, mean (SD) | 48.7 (12.6) | 49.1 (13.6) | 48.5 (10.6) |
| SOFAS score, mean (SD) | 50.1 (12.3) | 50.5 (13.0) | 49.9 (11.0) |
| CGI-S score, mean (SD) | 4.0 (0.8) | 4.0 (0.9) | 4.1 (0.6) |
| BPRS score, mean (SD) | 39.8 (11.3) | 39.8 (12.7) | 39.6 (8.2) |
aAt enrollment, 2 patients could not be characterized as early or later phase